Skip to main content
SpringerLink
Log in

Cannabinoid Control of Motor Function at the Basal Ganglia

  • Chapter
Cannabinoids

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 168))

Abstract

Classic and novel data strengthen the idea of a prominent role for the endocannabinoid signaling system in the control of movement. This finding is supported by three-fold evidence: (1) the abundance of the cannabinoid CB1 receptor subtype, but also of CB2 and vanilloid VR1 receptors, as well as of endocannabinoids in the basal ganglia and the cerebellum, the areas that control movement; (2) the demonstration of a powerful action, mostly of an inhibitory nature, of plant-derived, synthetic, and endogenous cannabinoids on motor activity, exerted by modulating the activity of various classic neurotransmitters; and (3) the occurrence of marked changes in endocannabinoid transmission in the basal ganglia of humans affected by several motor disorders, an event corroborated in animal models of these neurological diseases. This three-fold evidence has provided support to the idea that cannabinoid-based compounds, which act at key steps of the endocannabinoid transmission [receptors, transporter, fatty acid amide hydrolase (FAAH)], might be of interest because of their potential ability to alleviate motor symptoms and/or provide neuroprotection in a variety of neurological pathologies directly affecting basal ganglia structures, such as Parkinson’s disease and Huntington’s chorea, or indirectly, such as multiple sclerosis and Alzheimer’s disease. The present chapter will review the knowledge on this issue, trying to establish future lines for research into the therapeutic potential of the endocannabinoid system in motor disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 629.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 799.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Alexi T, Hughes PE, Faull RLM, Williams LE (1998) 3-Nitropropionic acid’s lethal triplet: cooperative pathways of neurodegeneration. Neuroreport 9:57–64

    Google Scholar 

  • Anderson LA, Anderson JJ, Chase TN, Walters JR (1995) The cannabinoid agonists WIN55, 212-2 and CP55,940 attenuate rotational behaviour induced by a dopamine D1 but not D2 agonist in rats with unilateral lesions of the nigrostriatal pathway. Brain Res 691:106–114

    Article  PubMed  CAS  Google Scholar 

  • Aroyo I, González S, Nuñez E, Lastres-Becker I, Sagredo O, Mechoulam R, Romero J, Ramos JA, Brouillet E, Fernández-Ruiz J (2005) Involvement of CB2 receptors in the neuroprotective effects of cannabinoids in rats with striatal atrophy induced by local application of malonate, an experimental model of Huntington’s disease. J Neurosci (submitted)

    Google Scholar 

  • Baker D, Pryce G (2003) The therapeutic potential of cannabis in multiple sclerosis. Expert Opin Investig Drugs 12:561–567

    PubMed  CAS  Google Scholar 

  • Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, Layward L (2000) Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404:84–87

    Article  PubMed  CAS  Google Scholar 

  • Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward L, Fezza F, Bisogno T, Di Marzo V (2001) Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 15:300–302

    PubMed  CAS  Google Scholar 

  • Beltramo M, Rodríguez de Fonseca F, Navarro M, Calignano A, Gorriti MA, Grammatikopoulos G, Sadile AG, Giuffrida A, Piomelli D (2000) Reversal of dopamine D2 receptor responses by an anandamide transport inhibitor. J Neurosci 20:3401–3407

    PubMed  CAS  Google Scholar 

  • Benito C, Nunez E, Tolon RM, Carrier EJ, Rabano A, Hillard CJ, Romero J (2003) Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer’s disease brains. J Neurosci 23:11136–11141

    PubMed  CAS  Google Scholar 

  • Berardelli A, Noth J, Thompson PD, Bollen EL, Curra A, Deuschl G, van Dijk JG, Topper R, Schwarz M, Roos RA (1999) Pathophysiology of chorea and bradykinesia in Huntington’s disease. Mov Disord 14:398–403

    Article  PubMed  CAS  Google Scholar 

  • Berrendero F, Sánchez A, Cabranes A, Puerta C, Ramos JA, García-Merino A, Fernández-Ruiz J (2001) Changes in cannabinoid CB1 receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse 41:195–202

    Article  PubMed  CAS  Google Scholar 

  • Bisogno T, Berrendero F, Ambrosino G, Cebeira M, Ramos JA, Fernández-Ruiz JJ, Di Marzo V(1999) Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem Biophys Res Commun 256:377–380

    Article  PubMed  CAS  Google Scholar 

  • Blandini F, Nappi G, Tassorelli C, Martignoni E (2000) Functional changes in the basal ganglia circuitry in Parkinson’s disease. Prog Neurobiol 62:63–88

    Article  PubMed  CAS  Google Scholar 

  • Brotchie JM (1998) Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson’s disease. Mov Disord 13:871–876

    Article  PubMed  CAS  Google Scholar 

  • Brotchie JM (2000) The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson’s disease. Ann Neurol 47:S105–S114

    PubMed  CAS  Google Scholar 

  • Brotchie JM (2003) CB1 cannabinoid receptor signalling in Parkinson’s disease. Curr Opin Pharmacol 3:54–61

    PubMed  CAS  Google Scholar 

  • Brouillet E, Conde F, Beal MF, Hantraye P (1999) ReplicatingHuntington’s disease phenotype in experimental animals. Prog Neurobiol 59:427–468

    Article  PubMed  CAS  Google Scholar 

  • Cabranes A, Venderova K, de Lago E, Fezza F, Valenti M, Sánchez A, García-Merino A, Ramos JA, Di Marzo V, Fernández-Ruiz J (2005) Decreased endocannabinoid levels in the brain and beneficial effects of certain endocannabinoid uptake inhibitors in a rat model of multiple sclerosis: involvement of vanilloid TRPV1 receptors. Neurobiol Dis (in press)

    Google Scholar 

  • Cadogan AK, Alexander SP, Boyd EA, Kendall DA (1997) Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum. J Neurochem 69:1131–1137

    PubMed  CAS  Google Scholar 

  • Carlsson A (2002) Treatment of Parkinson’s with L-DOPA. The early discovery phase, and a comment on current problems. J Neural Transm 109:777–787

    Article  PubMed  CAS  Google Scholar 

  • Cattaneo E, Rigamonti D, Goffredo D, Zuccato C, Squitieri F, Sipione S (2001) Loss of normal huntingtin function: new developments inHuntington’s disease research. Trends Neurosci 24:182–188

    Article  PubMed  CAS  Google Scholar 

  • Chan PK, Chan SC, Yung WH (1998) Presynaptic inhibition of GABAergic inputs to rat substantia nigra pars reticulata neurones by a cannabinoid agonist. Neuroreport 9:671–675

    PubMed  CAS  Google Scholar 

  • Chen Y, Swanson RA (2003) Astrocytes and brain injury. J Cereb Blood Flow Metab 23:137–149

    PubMed  Google Scholar 

  • Compton DR, Aceto MD, Lowe J, Martin BR (1996) In vivo characterization of a specific cannabinoid antagonis (SR141716A): inhibition of Δ9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 277:586–594

    PubMed  CAS  Google Scholar 

  • Consroe P (1998) Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol Dis 5:534–551

    Article  PubMed  CAS  Google Scholar 

  • Crawley JN, Corwin RL, Robinson JK, Felder ChC, Devane WA, Axelrod J (1993) Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacol Biochem Behav 46:967–972

    Article  PubMed  CAS  Google Scholar 

  • de Lago E, Fernandez-Ruiz J, Ortega-Gutierrez S, Viso A, Lopez-Rodriguez ML, Ramos JA (2002) UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide. Eur J Pharmacol 449:99–103

    PubMed  Google Scholar 

  • de Lago E, Ligresti A, Ortar G, Morera E, Cabranes A, Pryce G, Bifulco M, Baker D, Fernandez-Ruiz J, Di Marzo V (2004a) In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake. Eur J Pharmacol 484:249–257

    PubMed  Google Scholar 

  • de Lago E, de Miguel, Lastres-Becker I, Ramos JA, Fernández-Ruiz J (2004b) Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence. Brain Res 1007:152–159

    PubMed  Google Scholar 

  • de Lago E, Ortega S, López-Rodríguez ML, Ramos JA, Fernández-Ruiz J (2004c) Therapeutic potential of UCM707, an inhibitor of the endocannabinoid transport, in animal models of various neurological diseases. Mov Disord (submitted)

    Google Scholar 

  • Denovan-Wright EM, Robertson HA (2000) Cannabinoid receptor messenger RNA levels decrease in subset neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington’s disease mice. Neuroscience 98:705–713

    Article  PubMed  CAS  Google Scholar 

  • Desarnaud F, Cadas H, Piomelli D (1995) Anandamide amidohydrolase activity in rat brain microsomes. Identification and partial purification. J Biol Chem 270:6030–6035

    PubMed  CAS  Google Scholar 

  • Dewey WL (1986) Cannabinoid pharmacology. Pharmacol Rev 38:151–178

    PubMed  CAS  Google Scholar 

  • Di Marzo V, Melck D, Bisogno T, De Petrocellis L (1998) Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 21:521–528

    PubMed  Google Scholar 

  • Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM (2000a) Enhanced levels of endocannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson’s disease. FASEB J 14:1432–1438

    PubMed  Google Scholar 

  • Di Marzo V, Berrendero F, Bisogno T, Gonzalez S, Cavaliere P, Romero J, Cebeira M, Ramos JA, Fernandez-Ruiz J (2000b) Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of Δ9-tetrahydrocannabinol-tolerant rats. J Neurochem 74:1627–1635

    PubMed  Google Scholar 

  • Di Marzo V, Lastres-Becker I, Bisogno T, De Petrocellis L, Milone A, Davis JB, Fernandez-Ruiz J (2001) Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. Eur J Pharmacol 420:123–131

    PubMed  Google Scholar 

  • Dinh TP, Freund TF, Piomelli D (2002) A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids 121:149–158

    Article  PubMed  CAS  Google Scholar 

  • Factor SA, Friedman JH (1997) The emerging role of clozapine in the treatment of movement disorders. Mov Disord 12:483–496

    PubMed  CAS  Google Scholar 

  • Fernández-Espejo E, Caraballo I, Rodriguez de Fonseca F, El Banoua F, Ferrer B, Flores JA, Galan-Rodriguez B (2004) Homeostatic changes of anandamide synthesis, and functional effects of cannabinoid CB1 antagonists in rats with severe hemiparkinsonism. Neurobiol Dis (in press)

    Google Scholar 

  • Fernandez-Ruiz J, Lastres-Becker I, Cabranes A, Gonzalez S, Ramos JA (2002) Endocannabinoids and basal ganglia functionality. Prostaglandins Leukot Essent Fatty Acids 66:263–273

    Google Scholar 

  • Ferrer B, Asbrock N, Kathuria S, Piomelli D, Giuffrida A (2003) Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopainduced dyskinesias. Eur J Neurosci 18:1607–1614

    Article  PubMed  Google Scholar 

  • Fox SH, Henry B, Hill M, Crossman A, Brotchie J (2002a) Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson’s disease. Mov Disord 17:1180–1187

    PubMed  Google Scholar 

  • Fox SH, Kellett M, Moore AP, Crossman AR, Brotchie JM (2002b) Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov Disord 17:145–149

    PubMed  Google Scholar 

  • Francis PT, Webster MT, Chesell IP, Holmes C, Stratmann GC, Procter AW, Cross AJ, Green AR, Bouen DM (1993) Neurotransmitters and second messengers in aging and Alzheimer’s disease. Ann NY Acad Sci 695:19–26

    PubMed  CAS  Google Scholar 

  • Fride E, Mechoulam R (1993) Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol 231:313–314

    Article  PubMed  CAS  Google Scholar 

  • Gerdeman G, Lovinger DM (2001) CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol 85:468–471

    PubMed  CAS  Google Scholar 

  • Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Piomelli D (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2:358–363

    PubMed  CAS  Google Scholar 

  • Giuffrida A, Beltramo M, Piomelli D (2001) Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J Pharmacol Exp Ther 298:7–14

    PubMed  CAS  Google Scholar 

  • Glaser ST, Abumrad NA, Fatade F, Kaczocha M, Studholme KM, Deutsch DG (2003) Evidence against the presence of an anandamide transporter. Proc Natl Acad Sci USA 100:4269–4274

    Article  PubMed  CAS  Google Scholar 

  • Glass M, Faull RLM, Dragunow M (1993) Loss of cannabinoid receptors in the substantia nigra in Huntington’s disease. Neuroscience 56:523–527

    Article  PubMed  CAS  Google Scholar 

  • Glass M, Dragunow M, Faull RLM (2000) The pattern of neurodegeneration in Huntington’s disease: a comparative study of cannabinoid, dopamine, adenosine and GABA-A receptor alterations in the human basal ganglia in Huntington’s disease. Neuroscience 97:505–519

    Article  PubMed  CAS  Google Scholar 

  • González S, Romero J, de Miguel R, Lastres-Becker I, Villanúa MA, Makriyannis A, Ramos JA, Fernández-Ruiz J (1999) Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide. Life Sci 65:327–336

    PubMed  Google Scholar 

  • Gorriti MA, Rodríguez de Fonseca F, Navarro M, Palomo T (1999) Chronic (-)Δ9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats. Eur J Pharmacol 365:133–142

    Article  PubMed  CAS  Google Scholar 

  • Grundy RI (2002) The therapeutic potential of the cannabinoids in neuroprotection. Expert Opin Investig Drugs 11:1365–1374

    Article  PubMed  CAS  Google Scholar 

  • Gubellini P, Picconi B, Bari M, Battista N, Calabresi P, Centonze D, Bernardi G, Finazzi-Agro A, Maccarrone M (2002) Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J Neurosci 22:6900–6907

    PubMed  CAS  Google Scholar 

  • Gueudet C, Santucci V, Rinaldi-Carmona M, Soubrie P, Le Fur G (1995) The CB1 cannabinoid receptor antagonist SR141716A affects A9 dopamine neuronal activity in the rats. Neuroreport 6:1421–1425

    PubMed  CAS  Google Scholar 

  • Hemming M, Yellowlees PM (1993) Effective treatment of Tourette’s syndrome with marijuana. J Psychopharmacol 7:389–391

    Google Scholar 

  • Herkenham M, Lynn AB, Little MD, Melvin LS, Johnson MR, de Costa DR, Rice KC (1991a) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11:563–583

    PubMed  CAS  Google Scholar 

  • Herkenham M, Lynn AB, de Costa BR, Richfield EK (1991b) Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res 547:267–274

    Article  PubMed  CAS  Google Scholar 

  • Hersch SM, Ferrante RJ (1997) Neuropathology and pathophysiology of Huntington’s disease. In: Watts RL, Koller WC (eds) Movement disorders. Neurologic principles and practice. McGraw-Hill, New York, pp 503–518

    Google Scholar 

  • Hiltunen AJ, Jarbe TU, Wangdahl K (1988) Cannabinol and cannabidiol in combination: temperature, open-field activity, and vocalization. Pharmacol Biochem Behav 30:675–678

    Article  PubMed  CAS  Google Scholar 

  • Hohmann AG, Herkenham M (2000) Localization of cannabinoid CB1 receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. Synapse 37:71–80

    Article  PubMed  CAS  Google Scholar 

  • Itier JM, Ibanez P, Mena MA, Abbas N, Cohen-Salmon C, Bohme GA, Laville M, Pratt J, Corti O, Pradier L, Ret G, Joubert C, Periquet M, Araujo F, Negroni J, Casarejos MJ, Canals S, Solano R, Serrano A, Gallego E, Sanchez M, Denefle P, Benavides J, Tremp G, Rooney TA, Brice A, Garcia de Yebenes J (2003) Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet 12:2277–2291

    Article  PubMed  CAS  Google Scholar 

  • Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M, Izzo AA (2004) Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on betaamyloid-induced toxicity in PC12 cells. J Neurochem 89:134–141

    PubMed  CAS  Google Scholar 

  • Iversen L (2003) Cannabis and the brain. Brain 126:1252–1270

    Article  PubMed  Google Scholar 

  • Jarbe TU, Sheppard R, Lamb RJ, Makriyannis A, Lin S, Goutopoulos A (1998) Effects of Δ9-tetrahydrocannabinol and (R)-methanandamide on open-field behavior in rats. Behav Pharmacol 9:169–174

    PubMed  CAS  Google Scholar 

  • Kieburtz K (1999) Antiglutamate therapies in Huntington’s disease. J Neural Transm Suppl 55:97–102

    PubMed  CAS  Google Scholar 

  • Kurlan R, Richard IH, Papka M, Marshall F (2000) Movement disorders in Alzheimer’s disease: more rigidity of definitions is needed. Mov Disord 15:24–29

    Article  PubMed  CAS  Google Scholar 

  • Lastres-Becker I, Cebeira M, de Ceballos M, Zeng B-Y, Jenner P, Ramos JA, Fernández-Ruiz J (2001a) Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patientswith Parkinson’s syndromeand ofMPTP-treated marmosets. Eur J Neurosci 14:1827–1832

    Article  PubMed  CAS  Google Scholar 

  • Lastres-Becker I, Fezza F, Cebeira M, Bisogno T, Ramos JA, Milone A, Fernández-Ruiz JJ, Di Marzo V (2001b) Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington’s disease. Neuroreport 12:2125–2129

    PubMed  CAS  Google Scholar 

  • Lastres-Becker I, Hansen HH, Berrendero F, de Miguel R, Pérez-Rosado A, Manzanares J, Ramos JA, Fernández-Ruiz J (2002a) Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington’s disease. Synapse 44:23–35

    Article  PubMed  CAS  Google Scholar 

  • Lastres-Becker I, Gomez M, De Miguel R, Ramos JA, Fernández-Ruiz J (2002b) Loss of cannabinoid CB1 receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington’s disease. Neurotox Res 4:601–608

    Article  PubMed  CAS  Google Scholar 

  • Lastres-Becker I, Berrendero F, Lucas JJ, Martin-Aparicio E, Yamamoto A, Ramos JA, Fernández-Ruiz J (2002c) Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington;’s disease. Brain Res 929:236–242

    Article  PubMed  CAS  Google Scholar 

  • Lastres-Becker I, de Miguel R, De Petrocellis L, Makriyannis A, Di Marzo V, Fernández-Ruiz J (2003a) Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington’s disease. J Neurochem 84:1097–1109

    Article  PubMed  CAS  Google Scholar 

  • Lastres-Becker I, De Miguel R, Fernández-Ruiz J (2003b) The endocannabinoid system and Huntington’s disease. Curr Drug Target CNS Neurol Disord 2:335–347

    CAS  Google Scholar 

  • Lastres-Becker I, Bizat N, Boyer F, Hantraye P, Brouillet E, Fernández-Ruiz J (2003c) Effects of cannabinoids in the rat model of Huntington’s disease generated by an intrastriatal injection of malonate. Neuroreport 14:813–816

    PubMed  CAS  Google Scholar 

  • Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernández-Ruiz J (2004a) Cannabinoids provide neuroprotection in experimental models of Parkinson’s disease: involvement of their antioxidant properties and/or of glial cell-mediated effects. Neurobiol Dis (in press)

    Google Scholar 

  • Lastres-Becker I, Bizat N, Boyer F, Hantraye P, Fernández-Ruiz J, Brouillet E (2004b) Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo: implication for Huntington’s disease. Neuroreport 15:2375–2379

    PubMed  CAS  Google Scholar 

  • Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Böhme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283:401–404

    Article  PubMed  CAS  Google Scholar 

  • Maccarrone M, Gubellini P, Bari M, Picconi B, Battista N, Centonze D, Bernardi G, Finazzi-Agro A, Calabresi P (2003) Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. J Neurochem 85:1018–1025

    Article  PubMed  CAS  Google Scholar 

  • Mailleux P, Vanderhaeghen JJ (1992a) Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 48:655–668

    Article  PubMed  CAS  Google Scholar 

  • Mailleux P, Vanderhaeghen JJ (1992b) Age-related loss of cannabinoid of cannabinoid receptor binding sites and mRNA in the rat striatum. Neurosci Lett 147:179–181

    PubMed  CAS  Google Scholar 

  • Mailleux P, Vanderhaeghen JJ (1993) Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study. J Neurochem 61:1705–1712

    PubMed  CAS  Google Scholar 

  • Maneuf YP, Nash JE, Croosman AR, Brotchie JM (1996) Activation of the cannabinoid receptor by Δ9-THC reduces GABA uptake in the globus pallidus. Eur J Pharmacol 308:161–164

    Article  PubMed  CAS  Google Scholar 

  • Maneuf YP, Croosman AR, Brotchie JM (1997) The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson’s disease. Exp Neurol 148:265–270

    Article  PubMed  CAS  Google Scholar 

  • McLaughlin PJ, Delevan CE, Carnicom S, Robinson JK, Brener J (2000) Fine motor control in rats is disrupted by Δ9-tetrahydrocannabinol. Pharmacol Biochem Behav 66:803–809

    Article  PubMed  CAS  Google Scholar 

  • Meschler JP, Howlett AC (2001) Signal transduction interactions between CB1 cannabinoid and dopamine receptors in the rat and monkey striatum. Neuropharmacology 40:918–926

    Article  PubMed  CAS  Google Scholar 

  • Meschler JP, Howlett AC, Madras BK (2001) Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. Psychopharmacology (Berl) 156:79–85

    Article  PubMed  CAS  Google Scholar 

  • Mezey E, Toth ZE, Cortright DN, Arzubi MK, Krause JE, El de R, Guo A, Blumberg PM, Szallasi A (2000) Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci USA 97:3655–3660

    Article  PubMed  CAS  Google Scholar 

  • Miller A, Walker JM (1995) Effects of a cannabinoid on spontaneous and evoked neuronal activity in the substantia nigra pars reticulata. Eur J Pharmacol 279:179–185

    Article  PubMed  CAS  Google Scholar 

  • Miller A, Walker JM (1996) Electrophysiological effects of a cannabinoid on neural activity in the globus pallidus. Eur J Pharmacol 304:29–35

    Article  PubMed  CAS  Google Scholar 

  • Miller A, Sañudo-Peña MC, Walker JM (1998) Ipsilateral turning behavior induced by unilateral microinjections of a cannabinoid into the rat subthalamic nucleus. Brain Res 793:7–11

    Article  PubMed  CAS  Google Scholar 

  • Milton NG (2002) Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide. Neurosci Lett 332:127–130

    Article  PubMed  CAS  Google Scholar 

  • Moss DE, McMaster SB, Rogers J (1981) Tetrahydrocannabinol potentiates reserpine-induced hypokinesia. Pharmacol Biochem Behav 15:779–783

    Article  PubMed  CAS  Google Scholar 

  • Müller-Vahl KR (2003) Cannabinoids reduce symptoms of Tourette’s syndrome. Expert Opin Pharmacother 4:1717–1725

    PubMed  Google Scholar 

  • Müller-Vahl KR, Kolbe H, Schneider U, Emrich HM (1998) Cannabinoids: possible role in the pathophysiology of Gilles de la Tourette-syndrome. Acta Psychiatr Scand 98:502–506

    PubMed  Google Scholar 

  • Müller-Vahl KR, Schneider U, Kolbe H, Emrich HM (1999a) Treatment of Tourette-syndrome with Δ9-tetrahydrocannabinol. Am J Psychiatry 156:495

    PubMed  Google Scholar 

  • Müller-Vahl KR, Schneider U, Emrich HM (1999b) Nabilone increases choreatic movements in Huntington’s disease. Mov Disord 14:1038–1040

    PubMed  Google Scholar 

  • Müller-Vahl KR, Kolbe H, Schneider U, Emrich HM (1999c) Cannabis in movement disorders. Forsch Komplementarmed 6:23–27

    PubMed  Google Scholar 

  • Müller-Vahl KR, Schneider U, Koblenz A, Jobges M, Kolbe H, Daldrup T, Emrich HM (2002) Treatment of Tourette’s syndrome with Δ9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 35:57–61

    PubMed  Google Scholar 

  • Navarro M, Fernández-Ruiz JJ, de Miguel R, Hernández ML, Cebeira M, Ramos JA (1993) Motor disturbances induced by an acute dose of Δ9-tetrahydrocannabinol: possible involvement of nigrostriatal dopaminergic alterations. Pharmacol Biochem Behav 45:291–298

    Article  PubMed  CAS  Google Scholar 

  • Nuñez E, Benito C, Pazos MR, Barbachano A, Fajardo O, González S, Tolón R, Romero J (2004) Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study. Synapse 53:208–213

    PubMed  Google Scholar 

  • Page KJ, Besret L, Jain M, Monaghan EM, Dunnett BS, Everitt BJ (2000) Effects of systemic 3-nitropropionic acid-induced lesions of the dorsal striatum on cannabinoid and muopioid receptor binding in the basal ganglia. Exp Brain Res 130:142–150

    Article  PubMed  CAS  Google Scholar 

  • Pazos MR, Nuñez E, Benito C, Tolón R, Romero J (2004) Role of the endocannabinoid system in Alzheimer’s disease: new perspectives. Life Sci 75:1907–1915

    Article  PubMed  CAS  Google Scholar 

  • Pertwee RG (2002) Cannabinoids and multiple sclerosis. Pharmacol Ther 95:165–174

    Article  PubMed  CAS  Google Scholar 

  • Pertwee RG, Greentree SG, Swift PA (1988) Drugs which stimulate or facilitate central GABAergic transmission interact synergistically with Δ9-tetrahydrocannabinol to produce marked catalepsy in mice. Neuropharmacology 27:1265–1270

    PubMed  CAS  Google Scholar 

  • Reddy PH, Williams M, Tagle DA (1999) Recent advances in understanding the pathogenesis of Huntington’s disease. Trends Neurosci 22:248–255

    Article  PubMed  CAS  Google Scholar 

  • Richfield EK, Herkenham M (1994) Selective vulnerability in Huntington’s disease: preferential loss of cannabinoid receptors in lateral globus pallidus. Ann Neurol 36:577–584

    Article  PubMed  CAS  Google Scholar 

  • Richter A, Loscher W (1994) (+)-WIN 55,212-2, a novel cannabinoid receptor agonist, exerts antidystonic effects in mutant dystonic hamsters. Eur J Pharmacol 264:371–377

    PubMed  CAS  Google Scholar 

  • Richter A, Loscher W (2002) Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia. Eur J Pharmacol 454:145–151

    Article  PubMed  CAS  Google Scholar 

  • Rodriguez de Fonseca F, Gorriti MA, Fernández-Ruiz J, Palomo T, Ramos JA (1994) Down-regulation of rat brain cannabinoid binding sites after chronic Δ9-tetrahydrocannabinol treatment. Pharmacol Biochem Behav 47:33–40

    Google Scholar 

  • Romero J, García L, Cebeira M, Zadrozny D, Fernández-Ruiz J, Ramos JA (1995a) The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behaviour: role of nigrostriatal dopaminergic neurons. Life Sci 56:2033–2040

    Article  PubMed  CAS  Google Scholar 

  • Romero J, de Miguel R, García-Palomero E, Fernández-Ruiz J, Ramos JA (1995b) Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function. Brain Res 694:223–232

    Article  PubMed  CAS  Google Scholar 

  • Romero J, García-Palomero E, Lin SY, Ramos JA, Makriyannis A, Fernández-Ruiz J (1996a) Extrapyramidal effects of methanandamide, an analog of anandamide, the endogenous CB1 receptor ligand. Life Sci 58:1249–1257

    Article  PubMed  CAS  Google Scholar 

  • Romero J, García-Palomero E, Fernández-Ruiz J, Ramos JA (1996b) Involvement of GABA-B receptors in the motor inhibition produced by agonists of brain cannabinoid receptors. Behav Pharmacol 7:299–302

    PubMed  CAS  Google Scholar 

  • Romero J, de Miguel R, Ramos JA, Fernández-Ruiz J (1998a) The activation of cannabinoid receptors in striatonigral neurons inhibited GABA uptake. Life Sci 62:351–363

    PubMed  CAS  Google Scholar 

  • Romero J, Berrendero F, García-Gil L, de la Cruz P, Ramos JA, Fernández-Ruiz J (1998b) Loss of cannabinoid receptor binding and messenger RNA levels and cannabinoid agonist-stimulated [35S]-GTPγS binding in the basal ganglia of aged rats. Neuroscience 84:1075–1083

    Article  PubMed  CAS  Google Scholar 

  • Romero J, Berrendero F, Perez-Rosado A, Manzanares J, Rojo A, Fernández-Ruiz J, de Yébenes JG, Ramos JA (2000) Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen. Life Sci 66:485–494

    Article  PubMed  CAS  Google Scholar 

  • Romero J, Lastres-Becker I, de Miguel R, Berrendero F, Ramos JA, Fernández-Ruiz J (2002) The endogenous cannabinoid system and the basal ganglia. biochemical, pharmacological, and therapeutic aspects. Pharmacol Ther 95:137–152

    Article  PubMed  CAS  Google Scholar 

  • Sakurai-Yamashita Y, Kataoka Y, Fujiwara M, Mine K, Ueki S (1989) Δ9-Tetrahydrocannabinol facilitates striatal dopaminergic transmission. Pharmacol Biochem Behav 33:397–400

    PubMed  CAS  Google Scholar 

  • Sañudo-Peña MC, Walker JM (1997) Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat. J Neurophysiol 77:1635–1638

    PubMed  Google Scholar 

  • Sañudo-Peña MC, Patrick SL, Khen S, Patrick RL, Tsou K, Walker JM (1998) Cannabinoid effects in basal ganglia in a rat model of Parkinson’s disease. Neurosci Lett 248:171–174

    PubMed  Google Scholar 

  • Sañudo-Peña MC, Tsou K, Walker JM (1999) Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci 65:703–713

    PubMed  Google Scholar 

  • Sañudo-Peña MC, Romero J, Seale GE, Fernández-Ruiz J, Walker JM (2000) Activational role of cannabinoids on movement. Eur J Pharmacol 391:269–274

    PubMed  Google Scholar 

  • Schut LJ (1998) Motor system changes in the aging brain: what is normal and what is not. Geriatrics 53:S16–S19

    PubMed  Google Scholar 

  • Segovia G, Mora F, Crossman AR, Brotchie JM (2003) Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson’s disease. Mov Disord 18:138–149

    Article  PubMed  Google Scholar 

  • Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM (2001) Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: a pilot study. Neurology 57:2108–2111

    PubMed  CAS  Google Scholar 

  • Silverdale MA, McGuire S, McInnes A, Crossman AR, Brotchie JM (2001) Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson’s disease. Exp Neurol 169:400–406

    Article  PubMed  CAS  Google Scholar 

  • Skaper SD, Buriani A, Dal Toso R, Petrelli L, Romanello S, Facci L, Leon A (1996) The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci USA 93:3984–3989

    Article  PubMed  CAS  Google Scholar 

  • Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR (1994) The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther 270:219–227

    PubMed  Google Scholar 

  • Souilhac J, Poncelet M, Rinaldi-Carmona M, Le-Fur G, Soubrie P (1995) Intrastriatal injection of cannabinoid receptor agonists induced turning behavior in mice. Pharmacol Biochem Behav 51:3–7

    Article  PubMed  CAS  Google Scholar 

  • Szabo B, Dorner L, Pfreundtner C, Norenberg W, Starke K (1998) Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum. Neuroscience 85:395–403

    Article  PubMed  CAS  Google Scholar 

  • Szabo B, Muller T, Koch H (1999) Effects of cannabinoids on dopamine release in the corpus striatum and the nucleus accumbens in vitro. J Neurochem 73:1084–1089

    Article  PubMed  CAS  Google Scholar 

  • Szabo B, Wallmichrath I, Mathonia P, Pfreundtner C (2000) Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata. Neuroscience 97:89–97

    Article  PubMed  CAS  Google Scholar 

  • Tersigni TJ, Rosenberg HC (1996) Local pressure application of cannabinoid agonists increases spontaneous activity of rat substantia nigra pars reticulata neurons without affecting response to iontophoretically-applied GABA. Brain Res 733:184–192

    Article  PubMed  CAS  Google Scholar 

  • Tsou K, Brown S, Sañudo-Peña MC, Mackie K, Walker JM (1998a) Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83:393–411

    PubMed  CAS  Google Scholar 

  • Tsou K, Nogueron MI, Muthian S, Sañudo-Peña M, Hillard CJ, Deutsch DG, Walker JM (1998b) Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry. Neurosci Lett 254:137–140

    Article  PubMed  CAS  Google Scholar 

  • van der Stelt M, Di Marzo V (2003) The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol 480:133–150

    PubMed  Google Scholar 

  • Westlake TM, Howlett AC, Bonner TI, Matsuda LA, Herkenham M (1994) Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer’s brains. Neuroscience 63:637–652

    Article  PubMed  CAS  Google Scholar 

  • Wickens AP, Pertwee RG (1993) Δ9-Tetrahydrocannabinol and anandamide enhance the ability of muscimol to induce catalepsy in the globus pallidus of rats. Eur J Pharmacol 250:205–208

    Article  PubMed  CAS  Google Scholar 

  • Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362:1517–1526

    Article  PubMed  CAS  Google Scholar 

  • Zaretsky A, Rector NA, Seeman MV, Fornazzari X (1993) Current cannabis use and tardive dyskinesia. Schizophr Res 11:3–8

    Article  PubMed  CAS  Google Scholar 

  • Zeng BY, Dass B, Owen A, Rose S, Cannizzaro C, Tel BC, Jenner P (1999) Chronic LDOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats. Neurosci Lett 276:71–74

    Article  PubMed  CAS  Google Scholar 

  • Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI (1999) Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 96:5780–5785

    Article  PubMed  CAS  Google Scholar 

  • Zygmunt PM, Chuang H, Movahed P, Julius D, Hogestatt ED (2000) The anandamide transport inhibitor AM404 activates vanilloid receptors. Eur J Pharmacol 396:39–42

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Author notes

  1. J. Fernández-Ruiz

    Present address: Departamento de Bioquímica y Biología Molecular III, Facultad de Medicina, Universidad Complutense, Ciudad Universitaria s/n, 28040, Madrid, Spain

Authors and Affiliations

  1. Departamento de Bioquímica y Biología Molecular III, Facultad de Medicina, Universidad Complutense, Ciudad Universitaria s/n, 28040, Madrid, Spain

    S. González

Authors
  1. J. Fernández-Ruiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. González
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. School of Medical Sciences, Institute of Medical Science, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, Scotland, UK

    Roger G. Pertwee

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag

About this chapter

Cite this chapter

Fernández-Ruiz, J., González, S. (2005). Cannabinoid Control of Motor Function at the Basal Ganglia. In: Pertwee, R.G. (eds) Cannabinoids. Handbook of Experimental Pharmacology, vol 168. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-26573-2_16

Download citation

Publish with us

Policies and ethics

Search

Navigation